Next-Generation Neuroscience Is Here

We believe there’s a better way to treat central nervous system (CNS) conditions. Current treatments are not enough: they’re slow to take effect, have low response rates, and cause undesirable side effects. Gate Neurosciences is dedicated to developing a new generation of therapies for the hundreds of millions worldwide suffering from neurologic and psychiatric disorders.

Brain Health, Reimagined

We're on a mission to answer the unmet needs of people living with CNS conditions by developing safe, potent, and rapid-acting therapies that address underlying disease pathophysiology. Our therapeutic candidates are designed to function by enhancing neuroplasticity, strengthening neuronal connections, and rebalancing signaling to restore healthy brain function. By rethinking what’s possible, we’re creating hope for better treatments and better lives.


Our leadership team has devoted decades to the treatment of CNS conditions, giving us the deep expertise necessary for meaningful innovation.

Powered by Precision

Our approach focuses on smarter neuroscience development. We leverage precision medicine tools such as objective EEG biomarkers, patient responder analyses, and deep translational models combined with disciplined clinical execution to increase development success. As a result, our therapeutic candidates have maximum potential for patient impact. From neurodegenerative diseases to mood disorders, our platform offers a significant opportunity to more precisely address a broad set of diseases characterized by neuronal dysfunction.

See What’s Next in Neuroscience

We’re developing a growing portfolio of novel therapies for a broad range of neurologic and psychiatric disorders.


Our lead development programs, Zelquistinel (oral) and Apimostinel (injectable), are next-generation NMDAR modulators that in Phase 2a studies demonstrated a well-tolerated safety profile and statistically significant effects on clinical measures of antidepressant efficacy. Our therapeutic candidates are designed to provide a more direct approach to enhancing neuroplasticity through the NMDA receptor, without causing dissociation, hallucination, or ketamine-like side effects. Recent publications by Lee, 2020,  Pothula, 2021, and Duman, 2019, highlight our potent and differentiated mechanism versus NMDAR antagonists or channel blockers. Gate Neurosciences is planning to initiate a next Phase 2 study of Zelquistinel and biomarker study of Apimostinel in 2022.

Contact Us


11711 North Meridian Street
Suite 310
Carmel, IN 46032
United States